LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2

Li, Hui; Lei, Yuansheng; Li, Shuangxue; Li, Feng; Lei, Jieyun

doi:10.1007/s43032-022-00905-2

Cited by 7 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lncRNAs that were more frequently downregulated in different cohorts but that had not been previously related to EOC diagnosis were PGM5-AS1 , ENSG00000267058 , EPM2A-DT , NR2F1-AS1 , KLF3-AS1 , GLIDR , ERVK13-3 , and CLN8-AS1 , as shown in Figure 2 b. There were several lncRNAs that we considered to be contradictory from the results that we found in the meta-analyses ( Supplementary Materials, Table S3 ) and that were related to EOC in the literature, such as PART1 [ 18 ] or XIST [ 19 ]. This fact does not invalidate the experimental evidence collected about their role in EOC, although it downplays their importance as diagnostic biomarkers for the disease, since different trends are observed in different cohorts.…”

Section: Resultsmentioning

confidence: 86%

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Salamini-Montemurri

Lamas-Maceiras

Lorenzo-Catoira

et al. 2023

IJMS

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is one of the deadliest gynecological cancers worldwide, mainly because of its initially asymptomatic nature and consequently late diagnosis. Long non-coding RNAs (lncRNA) are non-coding transcripts of more than 200 nucleotides, whose deregulation is involved in pathologies such as EOC, and are therefore envisaged as future biomarkers. We present a meta-analysis of available gene expression profiling (microarray and RNA sequencing) studies from EOC patients to identify lncRNA genes with diagnostic and prognostic value. In this meta-analysis, we include 46 independent cohorts, along with available expression profiling data from EOC cell lines. Differential expression analyses were conducted to identify those lncRNAs that are deregulated in (i) EOC versus healthy ovary tissue, (ii) unfavorable versus more favorable prognosis, (iii) metastatic versus primary tumors, (iv) chemoresistant versus chemosensitive EOC, and (v) correlation to specific histological subtypes of EOC. From the results of this meta-analysis, we established a panel of lncRNAs that are highly correlated with EOC. The panel includes several lncRNAs that are already known and even functionally characterized in EOC, but also lncRNAs that have not been previously correlated with this cancer, and which are discussed in relation to their putative role in EOC and their potential use as clinically relevant tools.

show abstract

Section: Resultsmentioning

confidence: 86%

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Salamini-Montemurri

Lamas-Maceiras

Lorenzo-Catoira

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…RRM2 is the subunit of ribonucleotide reductase, getting involved in the production of deoxynucleic acid and nucleotide metabolism. Numerous studies suggest that RRM2 was dysregulated in various cancers, promoting the progression of cancers, such as renal cancer, liver cancer, lung cancer, breast cancer, colon cancer, ovarian cancer and bladder cancer [15][16][17][18][19][20][21]. In renal cancer, RRM2 was dramatically overexpressed in tumor tissue, causing poor prognosis of cancer patients [22].…”

Section: Ivyspringmentioning

confidence: 99%

Higher concentration of P7C3 than required for neuroprotection suppresses renal cell carcinoma growth and metastasis

Shu,

Chen,

Huang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Background: P7C3 is a novel compound that has been widely applied in neurodegenerative diseases and nerve injury repair. Here, we show that higher concentrations of P7C3 than are required for in vivo neuroprotection have the novel function of suppressing renal cell carcinoma (RCC) proliferation and metastasis. Methods: Colony formation, CCK-8 and EdU assay were applied to evaluate RCC cell proliferation. Wound healing and transwell assay were used to measure RCC cell migration and invasion. Flow cytometry assay was employed to detect RCC cell apoptosis and cell cycle. qRT-PCR assay was carried out to measure ribonucleotide reductase subunit M2 (RRM2) mRNA expression level, while western blot assay was utilized to detect the expression level of target proteins. RCC cell growth in vivo was determined by xenografts in mice. Results: We observed that high concentrations of P7C3 could restrain the proliferation and metastasis of RCC cells and promote cell apoptosis. Mechanistically, this new effect of higher dose of P7C3 was associated with reduced expression of RRM2, and the beneficial efficacy of P7C3 in RCC was blocked when suppression of RRM2 was prevented. When RRM2 suppression was permitted, the cGAS-STING pathway was activated by virtue of RRM2/Bcl-2/Bax signaling. Lastly, intraperitoneal injection of this high level of P7C3 in mice potently inhibited tumor growth. Conclusion: In conclusion, we show here that P7C3 that exerts an anti-cancer effect in RCC. Our study indicated that P7C3 might act as a novel drug for RCC in the future. The regulatory signal pathway RRM2/Bcl-2/BAX/cGAS-STING might present novel insight to the potential mechanism of RCC development.

show abstract

“…Examples of the former type of function have been seen in animal models of cervical squamous cell carcinoma ( Liu et al, 2020 ), gastric cancer ( Han et al, 2020 ) and glioma ( Deng et al, 2022 ) where up-regulation of PART1 has resulted in reduction of tumor growth. Animal models of colorectal carcinoma ( Zhou et al, 2020a ), hepatocellular carcinoma ( Pu et al, 2020 ), lung cancer ( Zhu et al, 2019 ), oral squamous cell carcinoma ( Yu et al, 2021 ), ovarian cancer ( Li et al, 2022b ) and triple negative breast cancer ( Cruickshank et al, 2021 ).…”

Section: Role Of Part1 In Cancersmentioning

confidence: 99%

A review on the role of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in the etiology of different disorders

Ghafouri‐Fard

Harsij²,

Hussen³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

LncRNA prostate androgen-regulated transcript 1 (PART1) is an important lncRNA in the carcinogenesis whose role has been firstly unraveled in prostate cancer. Expression of this lncRNA is activated by androgen in prostate cancer cells. In addition, this lncRNA has a role in the pathogenesis intervertebral disc degeneration, myocardial ischemia-reperfusion injury, osteoarthritis, osteoporosis and Parkinson’s disease. Diagnostic role of PART1 has been assessed in some types of cancers. Moreover, dysregulation of PART1 expression is regarded as a prognostic factor in a variety of cancers. The current review provides a concise but comprehensive summary of the role of PART1 in different cancers and non-malignant disorders.

show abstract

LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2

Cited by 7 publications

References 34 publications

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

Higher concentration of P7C3 than required for neuroprotection suppresses renal cell carcinoma growth and metastasis

A review on the role of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in the etiology of different disorders

Contact Info

Product

Resources

About